Inogen (INGN)
(Delayed Data from NSDQ)
$12.51 USD
+0.29 (2.37%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $12.49 -0.02 (-0.16%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$12.51 USD
+0.29 (2.37%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $12.49 -0.02 (-0.16%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth A Momentum A VGM
Zacks News
CVS Health (CVS) Deploys Time-Delay Safes in Georgia Pharmacies
by Zacks Equity Research
CVS Health's (CVS) time-delay safes are anticipated to help reduce robbery incidents.
Thermo Fisher (TMO) End Markets Rebound as COVID-19 Cases Drop
by Zacks Equity Research
In academic and government end markets, Thermo Fisher (TMO) grows on robust customer activity globally.
Medtronic (MDT) Progresses in Neuromodulation on New FDA Nod
by Zacks Equity Research
Medtronic's (MDT) SenSight claims to deliver patient-specific DBS therapy for the treatment of symptoms associated with Parkinson's, dystonia and essential tremor and medically refractory epilepsy.
Here's Why You Should Retain CVS Health (CVS) in Your Portfolio
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS) on solid first-quarter performance and growth in digital health services.
STERIS (STE) Expands Product Suite With New Acquisition
by Zacks Equity Research
STERIS' (STE) acquisition of Cantel Medical will complement and broaden the former's product and service offerings, global reach and customers.
Inogen (INGN) Down 11.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Add Inogen (INGN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its direct-to-customer business model and a strong product portfolio.
Inogen (INGN) Q1 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Inogen (INGN) gains traction from revenue growth within its Rental segment in Q1.
Inogen (INGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 89.29% and 8.44%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
4 Medical Products Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Rebound in base sales make us optimistic about OMI, INGN, XRAY and CNTG's results this time around.
Inogen's (INGN) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Inogen, Inc. (INGN).
Owens & Minor (OMI) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Owens & Minor (OMI) witnesses rebound in demand for elective procedures through the months of Q1.
InMode (INMD) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
InMode's (INMD) Morpheus8 Platform and Morpheus8 Body that use RF fractional technology are expected to have continued to contribute to the company's Q1 top line.
Why Is Inogen (INGN) Down 9.4% Since Last Earnings Report?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inogen (INGN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Inogen's (INGN) fourth-quarter results benefit from higher rental revenues and strength in business-to-business revenues.
Inogen (INGN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 17.86% and 6.92%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Inogen (INGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inogen (INGN) Up 35.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inogen (INGN) Stock Loses 9.2% After Delivering Loss in Q3
by Zacks Equity Research
Inogen (INGN) saw revenue decline within its Sales segment in Q3
Inogen (INGN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of -300.00% and -0.82%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Inogen (INGN) Q3 Earnings Expected to Decline
by Zacks Equity Research
Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inogen (INGN) Down 17.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Inogen in Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Inogen (INGN) stock, thanks to solid prospects
Inogen's (INGN) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Inogen (INGN) saw growth in revenues within its Rental segment in Q2.
Inogen (INGN) Q2 Earnings Beat Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 250.00% and -10.08%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?